INVU · Investview, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $36.26M | $52.38M | $67.92M | $61.85M | $38.27M | $24.18M |
| Cost of Revenue | - | - | - | - | - | $2.51M |
| Gross Profit | - | - | - | - | - | $21.68M |
| R&D | - | - | - | - | - | - |
| SG&A | $9.57M | $8.02M | $560.1K | $58.6K | $891.2K | $1.70M |
| Total Operating Expenses | $44.52M | $50.69M | $63.32M | $70.46M | $37.50M | $33.28M |
| D&A | $730.3K | $3.88M | $4.45M | $3.42M | $476.5K | $490.6K |
| Operating Income | ($8.26M) | $1.69M | $4.60M | ($8.61M) | $774.4K | ($9.09M) |
| Interest Expense | - | - | - | - | $30.0K | $30.0K |
| Income Tax | ($58.8K) | $894.9K | $2.18M | $326.6K | $149.6K | $7.4K |
| Net Income | ($8.91M) | $1.19M | $2.83M | ($12.94M) | $565.8K | ($21.29M) |
| EPS - Basic | ($0.01) | $0.00 | $0.00 | ($0.01) | $0.00 | - |
| EPS - Diluted | ($0.01) | $0.00 | $0.00 | ($0.01) | $0.00 | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.99M | $22.47M | $20.91M | $20.47M | $31.00M | $137.2K |
| Accounts Receivable | $569.6K | $2.53M | $500.0K | $1.26M | $1.92M | $905.1K |
| Inventory | $663.0K | $495.9K | - | $249.5K | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $13.00M | $28.52M | $24.45M | $26.02M | $35.92M | $6.60M |
| Total Assets | $21.50M | $31.57M | $33.69M | $35.58M | $51.50M | $10.40M |
| Current Liabilities | $6.11M | $12.29M | $12.04M | $11.77M | $13.58M | $20.72M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $12.57M | $14.37M | $14.90M | $18.20M | $22.56M | $24.66M |
| Stockholders' Equity | $8.92M | $17.20M | $18.79M | $17.37M | $28.94M | ($14.26M) |
| Retained Earnings | ($96.79M) | ($87.21M) | ($87.58M) | ($89.59M) | ($75.83M) | ($46.38M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.70M) | $8.30M | $6.07M | $9.36M | $6.89M | $4.62M |
| Investing Cash Flow | ($4.21M) | ($1.60M) | ($2.54M) | ($14.17M) | ($2.93M) | ($5.25M) |
| Financing Cash Flow | ($4.57M) | ($5.37M) | ($3.87M) | ($6.31M) | $2.57M | $624.4K |
| CapEx | $544.6K | $461.9K | $2.56M | $15.27M | $2.93M | $5.25M |
| Free Cash Flow | ($4.24M) | $7.84M | $3.50M | ($5.91M) | $3.95M | ($620.8K) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | 89.6% |
| Operating margin | -22.8% | 3.2% | 6.8% | -13.9% | 2.0% | -37.6% |
| EBITDA margin | -20.8% | 10.6% | 13.3% | -8.4% | 3.3% | -35.6% |
| Net margin | -24.6% | 2.3% | 4.2% | -20.9% | 1.5% | -88.0% |
| Free cash flow margin | -11.7% | 15.0% | 5.2% | -9.6% | 10.3% | -2.6% |
| FCF / Net income | 0.48 | 6.58 | 1.24 | 0.46 | 6.99 | 0.03 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 26.4% | 15.3% | 0.8% | 0.1% | 2.3% | 7.0% |
| Effective tax rate | - | 42.9% | 43.5% | - | 20.9% | - |
| Return on assets | -41.5% | 3.8% | 8.4% | -36.4% | 1.1% | -204.7% |
| Return on equity | -99.9% | 6.9% | 15.1% | -74.5% | 2.0% | 149.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.13 | 2.32 | 2.03 | 2.21 | 2.65 | 0.32 |
| Quick ratio | 2.02 | 2.28 | 2.03 | 2.19 | 2.65 | 0.32 |
| Cash ratio | 1.64 | 1.83 | 1.74 | 1.74 | 2.28 | 0.01 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | 25.8x | -303.1x |
| Equity multiplier | 2.41 | 1.84 | 1.79 | 2.05 | 1.78 | -0.73 |
| Liabilities / Assets | 0.58 | 0.46 | 0.44 | 0.51 | 0.44 | 2.37 |
| Efficiency | ||||||
| Asset turnover | 1.69 | 1.66 | 2.02 | 1.74 | 0.74 | 2.33 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 6d | 18d | 3d | 7d | 18d | 14d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -30.8% | -22.9% | 9.8% | 61.6% | 58.3% | - |
| Revenue CAGR (3y) | -16.3% | 11.0% | 41.1% | - | 28.8% | 468.7% |
| Revenue CAGR (5y) | 8.4% | - | 30.5% | 242.4% | 155.1% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | -63.2% | - | - | - | -130.7% |
| Net income growth (YoY) | - | -57.9% | - | - | - | -327.6% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | 123.7% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -48.1% | -8.5% | 8.1% | -40.0% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$72.56M totalMembership Revenue$29.22M · 40.3%
Foreign Revenue$24.90M · 34.3%
Domestic Revenue$11.40M · 15.7%
Health And Wellness Revenue$3.64M · 5.0%
Mining Revenue$3.31M · 4.6%
Other$86.7K · 0.1%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-2.80
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Business Services, NEC
Comparing Investview against the 5 most active filers in the same SIC group.